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ABSTRACT
Objectives: We evaluated the cost-effectiveness of a low-cost cholera
vaccine licensed and used in Vietnam, using recently collected data from
four developing countries where cholera is endemic. Our analysis incor-
porated new ﬁndings on vaccine herd protective effects.
Methods: Using data from Matlab, Bangladesh, Kolkata, India, North
Jakarta, Indonesia, and Beira, Mozambique, we calculated the net public
cost per disability-adjusted life year avoided for three immunization strat-
egies: 1) school-based vaccination of children 5 to 14 years of age; 2)
school-based vaccination of school children plus use of the schools to
vaccinate children aged 1 to 4 years; and 3) community-based vaccination
of persons aged 1 year and older.
Results: We determined cost-effectiveness when vaccine herd protection
was or was not considered, and compared this with commonly ac-
cepted cutoffs of gross domestic product (GDP) per person to classify
interventions as cost-effective or very-cost effective. Without including
herd protective effects, deployment of this vaccine would be cost-effective
only in school-based programs in Kolkata and Beira. In contrast, after
considering vaccine herd protection, all three programs were judged very
cost-effective in Kolkata and Beira. Because these cost-effectiveness calcu-
lations include herd protection, the results are dependent on assumed
vaccination coverage rates.
Conclusions: Ignoring the indirect effects of cholera vaccination has led to
underestimation of the cost-effectiveness of vaccination programs with
oral cholera vaccines. Once these effects are included, use of the oral killed
whole cell vaccine in programs to control endemic cholera meets the per
capita GDP criterion in several developing country settings.
Keywords: Beira, cholera, cost-effectiveness, herd protection, Jakarta,
Kolkata, Matlab, vaccines.
Introduction
Cholera is an infectious disease caused by exposure to the bac-
terium Vibrio cholerae O1 or O139, resulting in acute dehy-
dration and sometimes death. In 2006, the World Health
Organization (WHO) reported more than 236,000 cases world-
wide and 6311 deaths, although these estimates are widely
regarded as low due to underreporting [1]. The reemergence of
cholera in parts of West Africa, and the continuing problem of
cholera in East Africa and several parts of Asia have prompted
increasing concern over vulnerability to infection of poor popu-
lations living in unsanitary conditions. Multilateral aid organi-
zations such as the WHO have become interested in the potential
of oral cholera vaccines for reducing such risks.
The conventional wisdom among public health experts is that
prevention through improved sanitation and hygiene is the best
method for controlling cholera. Unfortunately, this objective
remains difﬁcult to achieve in many locations, particularly in
fast-expanding urban slums. Severe cholera is easily treatable
with intravenous rehydration therapy if the patient is diagnosed
promptly and has access to health care facilities, although recent
cholera outbreaks in situations with inadequate health care have
documented case fatality rates on the order of 20% and higher
[2]. Another approach is to combine prevention and prepared-
ness activities. This strategy might motivate more widespread use
of newly developed oral cholera vaccines [3–10].
There are two internationally licensed oral cholera vaccines:
the two-dose killed whole cell, recombinant B-subunit (WC/rBS)
vaccine (Dukoral), produced by the Dutch company, Crucell
(Leiden, The Netherlands); and the single-dose live attenuated
CVD 103Hgr (Orochol), originally manufactured by Berna
Biotech of Switzerland but no longer available. Both vaccines are
used mainly by travelers from developed countries [3–8]. Field
trials of WC/rBS vaccine in Bangladesh, Peru, and Mozambique
indicated 80% protection for 6 months followed by declining
effectiveness with time and a cumulative 50% protection for 3
years [4–6,8].
A modiﬁed version of the WC/rBS vaccine (containing only
killed whole cells without the B subunit, also referred to as the WC
vaccine) is produced in Vietnam and has been found to confer
protection similar to WC/rBS [11]. Initial studies in Vietnam
showed 66% effectiveness in the ﬁrst year and 50% effectiveness
over 3 to 5 years [9,10]. This vaccine has been modiﬁed to comply
with WHO standards and is being evaluated in a large Phase III
clinical trial in Kolkata, India [12]. It is anticipated that it will soon
be manufactured by producers in India and other developing
countries and will be available at a low price for public health
programs in cholera-endemic countries.
Recent reanalyses of data from the Bangladesh trial have
demonstrated that use of oral cholera vaccines conferred signiﬁ-
cant herd protection, through diminished risk of infection among
nonvaccinees and enhanced protection of vaccinees who reside in
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vaccinated neighborhoods [13,14]. Such herd effects will increase
the cost-effectiveness of vaccines.
The growing body of evidence from oral cholera vaccine
interventions can be analyzed to assess the cost-effectiveness of
cholera immunization strategies in different locations around the
world. A number of studies have previously examined the cost-
effectiveness of prevention and treatment of cholera. The Disease
Control Priorities (DCP) Project recently published a review of
published evidence that ranks cholera immunization for infants
with WC/rBS vaccine among the least cost-effective interventions
targeting diarrheal disease, with cost-effectiveness ratios of
US$1402 to US$8357 per disability-adjusted life year (DALY)
averted [11]. The ratio for cholera vaccines was lowest in Sub-
Saharan Africa, but still exceeded $1500. Consistent with these
results, Murray et al. [15] found that the same vaccine was less
cost-effective (about $3000/DALY averted) for preventing
cholera in endemic situations than several other control strate-
gies, including cholera disease treatment ($10–160/DALY
averted) and water and sanitation improvements such as
improved water supply plus latrine construction ($430/DALY
averted). Murray et al. also emphasize that the cost-effectiveness
results for cholera vaccination are highly sensitive to the cost of
the vaccine.
The present research, coordinated by the International
Vaccine Institute through the Diseases of the Most Impoverished
(DOMI) Program, improves the economic assessment of oral
cholera vaccine programs by more carefully measuring the
demand for vaccines and the economic costs of illness in three
countries in Asia (Bangladesh, India, Indonesia) and one in
Africa (Mozambique). The study combines these economic
factors with site-speciﬁc epidemiological information to conduct
the ﬁrst multicountry cost-effectiveness analyses (CEA) of
cholera vaccination options. This study is also the ﬁrst CEA to
include cholera vaccine herd protection and the ﬁrst to consider
the low-cost vaccine that can be produced in Asia today.
Methods
Study Sites
Our study sites were locations where the DOMI prospective
disease surveillance and economic studies took place. In Bang-
ladesh, the study was conducted in Matlab (pop. 220,000), a
seasonally ﬂood-prone rural area 50 km southeast of Dhaka.
Research on endemic cholera is well established through
the International Center for Diarrheal Disease Research—
Bangladesh (ICDDR–B). Our cost-effectiveness model assumed
that the entire area (roughly 180 km2) could be targeted by a
cholera immunization effort. In India, we analyzed the effects of
vaccinating residents of Tiljala and Narkeldanga (combined pop.
185,000), two densely populated slums in Kolkata with high
cholera incidence. The surveillance studies took place in Nar-
keldanga, while the economic demand studies were conducted in
Tiljala. In Indonesia, we examined programs in the surveillance
areas of Tanjung Priok and Koja (combined pop. 161,000), high-
incidence districts of North Jakarta. For Beira (pop. 550,000), a
city in Mozambique confronted with seasonal ﬂooding and
endemic cholera, we analyzed city-wide vaccination programs.
Analytical Approach
Our cost-effectiveness model closely follows the approach
described in the DCP Project and WHO’s CHOICE project
[11,16]. We assumed a one-time vaccination program in which
the WC vaccine was administered orally in two doses distributed
at two-week intervals. Health outcomes were calculated for the
duration of the vaccine’s efﬁcacy.
Our model considered three different age groups: 1) young
children, aged 1 to 4 (children below the age of 1 cannot be
vaccinated); 2) school-aged children, 5 to 14 years; and 3) adults,
ages 15 years and older. These cohorts corresponded to logical
vaccination program options in the study locations: school-based
programs focused on children ages 5 to 14 (Option 1); programs
for all eligible children (ages 1 to 14) held at school-based vac-
cination outposts, with young children being brought in by
parents or siblings (Option 2); and community-based vaccination
programs for all age groups held in clinics or other outposts
(Option 3). We assumed for simplicity that coverage rates among
school-aged children in Options 1 and 2 would be similar to
coverage rates in Option 3, although we recognize that school-
based vaccination may allow for higher coverage in this age
group than community-based vaccination. However, many of
our sites may also have low rates of school attendance.
Unlike the WHO CHOICE approach, we took a public sector
ﬁnancial perspective. The numerator of the cost-effectiveness
ratio is net public cost: total vaccination costs less publicly-borne
costs of illness (COI) prevented by vaccination (discounted using
a 3% real rate).
Vaccine manufacturing and delivery costs were assumed to be
borne by the public sector (either government or donors), and we
assumed that no user fees were collected from vaccine recipients.
The alternative CHOICE methodology would also include private
COI as a cost offset for the vaccination program, but we note that
this approach does not account for the private costs of vaccination
(travel and queuing), which in some locations could outweigh
private COI savings (Jeuland M, Lucas M, Clemens J, Whittington
D, unpubl. data). Cost-effectiveness results from a social perspec-
tive, which would include these two elements of private costs, are
presented in the journal’s online supplementary materials.
The Cost-Effectiveness Calculations
We ﬁrst assessed the baseline burden of cholera disease in terms of
cases, deaths, and DALYs for each of i age groups over the t years
of the program in the four study sites. DALYs incorporate both
reductions in morbidity (years of life lost to disability, YLD) and
mortality (years of life lost, YLL). We used uniform age weights
that applied the same value to an extra year of life regardless of the
age of the recipient. We also used country-speciﬁc life expectancies
(LE) from WHO life tables (available at: http://www.who.
int/whosis/database/life_tables/life_tables.cfm) to calculate the
number of life years saved for each age group and derived dis-
counted life years saved using a 3% real discount rate. To calculate
the DALYs avoided under different program options, we applied
Equations 1–4:
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where Efft is the effectiveness of the vaccine in year t, Coveri is the
percentage of age group i that would be vaccinated if the vaccine
were provided for free, CFRi, Ii and Ni are the case fatality rate,
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cholera incidence and number of people in age group i, Length is
the disease’s average duration, and Dur is the vaccine duration.
We report commonly used thresholds for cost-effective inter-
ventions. These thresholds compare net public cost per DALY
to per capita income in the countries of interest (obtained from
the International Monetary Fund’s World Economic Outlook,
April 2007). A “very cost-effective” intervention has a cost-
effectiveness ratio less than per capita GDP; a “cost-effective”
intervention has a ratio less than three times per capita GDP.
Falling below these thresholds, however, indicates nothing about
the cost-effectiveness of cholera vaccination in comparison to
other types of health interventions. Financial resources for health
are extremely limited in settings such as these study sites, and
other health interventions that also pass these thresholds may
have more attractive ratios.
Base-Case and Sensitivity Analysis
The ﬁrst step in our cost-effectiveness analysis was to calculate
the cost-effectiveness ratios of the three program options for the
“base-case” set of parameter values presented in Table 1. We did
these calculations twice. First, we used the standard vaccine
effectiveness commonly cited in the literature. Then, we devel-
oped a mathematical relationship to account for herd protection
which relates “overall” effectiveness to coverage rates in the
population, as described below. All other parameters were kept
the same.
Next, we investigated the impact of uncertainty in model
parameters on cost-effectiveness outcomes. We systematically
varied individual parameters over the uncertainty ranges listed in
Table 1 while keeping all other parameters at their base case
values. We then constructed tornado diagrams to see which ones
contributed the most to uncertainty in model outcomes. In the
interest of space, we do not present the tornado diagrams for all
sites, but rather consolidate these results into one table.
Herd Protection Assumptions
In their recent article detailing the beneﬁts of herd protective
effects of killed oral cholera vaccines in Matlab, Bangladesh, Ali
et al. showed that cholera incidence in placebo recipients in the
year following vaccination was highly dependent on vaccine
coverage rates in their neighborhoods [13]. They also found that
the cholera incidence in vaccine recipients varied inversely with
vaccine coverage. Longini et al. [14] used these data to construct
epidemiological models predicting vaccine effectiveness as a func-
tion of vaccine coverage.
To illustrate the implications of these ﬁndings, we conducted
two parallel sets of CEAs, in which all parameters were kept the
same except for vaccine effectiveness. We assumed that the popu-
lation in each location is static and that baseline incidence is
constant over the three years of the intervention. Calculations in
the ﬁrst analysis ignored herd protection effects. Protection
afforded by the vaccine was assumed to be 60% for the ﬁrst two
Table 1 Description of sites and model parameters, with uncertainty ranges in brackets*
Parameters Matlab, Bangladesh Kolkata, India† N. Jakarta, Indonesia Beira, Mozambique
Site-speciﬁc parameters
Population 220,000 185,000 161,000 550,000
Description Rural 2 poor urban slums 2 poor urban districts Citywide, urban and semiurban
Age of surveillance All ages All ages All ages All ages 1 years
Dates of surveillance 1994–2003 May ’03–Apr ’05 Aug ’01–Jul ’03 Dec ’03–Jan ’04‡
High cost-effectiveness threshold:
GDP/capita§ (2007 US$)
486 871 1,812 382
Incidence (cases/1,000)
<1 years 4.6 [2.3–9.2] 7.2 [3.6–14.3] 4.0 [2.0–8.0] N/A
1–4 years 3.8 [1.9–7.5] 7.0 [3.5–14.0] 1.5 [0.8–3.1] 8.8¶ [4.4–17.6]
5–14 years 1.6 [0.8–3.1] 2.2 [1.1–4.4] 0.3 [0.1–0.6] 2.9 [1.4–5.7]
15+ years 1.0 [0.5–2.1] 0.9 [0.5–1.8] 0.3 [0.1–0.5] 3.8 [1.9–7.7]
Public COI (2007 US$)
Overall 19 [10–38] 18 [9–36] 25 [13–52] 28 [14–56]
1–4 years 20 [10–40] 15 [8–30] 26 [13–52] 26 [13–52]
5–14 years 20 [10–40] 15 [8–30] 26 [13–52] 26 [13–52]
15+ years 18 [9–36] 20 [10–40] 24 [12–48] 30 [15–60]
Vaccine delivery cost (2007 US$/dose) 0.5 [0.3–2.5] 0.5 [0.3–2.5] 1.0 [0.6–5.0] 0.5 [0.3–2.5]
Vaccine purchase price (2007 US$/dose) 0.6 [0.4–0.8] 0.6 [0.4–0.8] 0.6 [0.4–0.8] 0.6 [0.4–0.8]
Percent coverage if vaccine is free (%)
1–4 years 64 [48–88] 74 [60–85] 52 [39–60] 53 [40–86]
5–14 years 55 [41–89] 55 [40–63] 38 [29–44] 59 [44–65]
15+ years 34 [26–53] 56 [40–62] 24 [18–26] 61 [46–67]
Parameters assumed to be the same across sites
Effectiveness of vaccine
No herd protection 0.6** [0.5–0.7]
Overall protection Varies††
Duration of vaccine (years) 3 [2–4]
Length of illness (days) 4 [2–8]
DALY weight 0.105 [0.08–0.27]
Case fatality rate (%) 1 [0.5–3]
Discount rate (%) 3
Campaign coverage (%) 80 [60–100]
*Base case value shown, with uncertainty range in brackets.
†Only the neighborhoods of Tiljala and Narkeldanga are included.
‡Surveillance conducted during a case-control study of vaccination effectiveness held in Beira.
§From country statistics on GDP per capita (IMF, World Economic Outlook Database, 2008).
¶Only 2 to 4 year olds.
**Overall effectiveness beyond the second year is assumed to be 17% less than in years 1 and 2, equivalent to a base case reduction from 60 to 50%.
††In the base case, overall vaccine effectiveness varies depending on coverage level, as shown in Figure 1. For the sensitivity analysis, the vaccine protection effect is assumed to range from no
reduction in overall effectiveness to a 33% reduction in all years.This parameter is referred to as Herd Extent in Table 5.
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years following vaccination, declining to 50% effectiveness in the
third year, consistent with evidence from the Vietnamese ﬁeld
trial [9]. The second analysis shows how ratios change when herd
protection effects are incorporated. We speciﬁed two simple rela-
tionships for effectiveness—“total protection” for the vaccinated,
and “indirect protection” for the unvaccinated as a function of
population coverage based on data from Ali et al. using the
approach outlined in the supporting information for Cook et al.
[17]. This analysis yields predictions for “overall” protection
(protection in the entire population) that are consistent with the
models described in Longini et al. [14], as shown in Figure 1. We
modeled third year overall effectiveness with herd protection
declining by the same percentage (17%) as in the ﬁrst analysis.
We allowed the duration of the protection to vary from 2 to 4
years, with 3 years in the base case.
Other Model Parameters
The site-speciﬁc and general parameters for the cost-effectiveness
model are shown in Table 1 for both the base case and the ranges
for sensitivity analyses.
Incidence. The epidemiological data came from prospective
population-based surveillance conducted by the DOMI program
in three sites (Kolkata, N. Jakarta and Beira) and from long-term
surveillance conducted by the ICDDR,B in Matlab, Bangladesh
[18]. These incidence rates may underestimate the true incidence
of cholera because they are based on passive surveillance studies.
As a result, we test the sensitivity of the cost-effectiveness ratios
to a wide range of incidence rates, spanning from half of the
ﬁeld-measured rates to two times those rates.
Case fatality rates (CFRs). Because our study sites had health care
systems prepared to handle cholera cases, CFRs were low. The
WHO reports CFRs for our countries ranging from 0.1% in India
in 2004 to 1.1 and 1.4% in Mozambique and Indonesia, respec-
tively, in 2005 [1,19] (Bangladesh did not report to the WHO in
2004 and 2005). Though high CFRs—20% or higher—have been
observed in recent cholera outbreaks in situations with inadequate
health care [2,15], we believe that 1 percent CFRs are probably
reasonable, and use it for the base case. Our uncertainty range
goes from 0.5 to 3% in all four study sites.
DALY weights. Because there are no published DALY weights
speciﬁc to cholera, we adopted the 0.105 standard applicable for
diarrheal disease during the period of illness [20]. This 0.105
weight that we use may understate the pain and suffering that
cholera patients endure, but the short duration of the disease
means that the morbidity burden has little effect on cost-
effectiveness ratios. Our uncertainty range goes from 0.08 (dengue
fever) to 0.27 (diseases such as malaria, Japanese encephalitis, and
acute upper respiratory infections).We assumed that the average
patient was sick for 4 days (range 2–8 days), with no long-term
health effects for recovered patients, as treatment with intrave-
nous rehydration therapy leads to quick recovery.
Cost of illness. The DOMI project included studies to estimate
the public cost of illness (COI) associated with cholera cases in the
four study locations (Poulos C, Riewpaiboon A, Stewart JF, et al.,
unpubl. data). Following the approach of the DCP [11], these COI
estimates were not adjusted for purchasing power parity. These
data have not been published, so some additional explanation is
warranted. Table 2 (from Poulos et al.) presents a summary of the
information that was collected in the COI studies.
The studies used standardized household surveys—
administered to culture-conﬁrmed patients at 7 and 14 days after
the laboratory conﬁrmation—to collect information on private
COI. For adult cases, the patient was interviewed; for children, an
adult in the household identiﬁed as familiar with the episode and
household ﬁnances was interviewed. The questionnaires included
questions for determining direct and indirect costs. Direct costs
included the costs of medical treatment, transportation, food,
lodging, and other special items. The indirect costs included 1) lost
wages due to lost work time by the patients, their caregivers, and
their substitutes, and 2) productivity losses due to forgone non-
market activities such as school, housework, and childcare. The
monetary value of nonmarket activities was estimated from the
subject’s age and the type of activity displaced [20].
To measure public costs of illness, data from health facilities
providing treatment were obtained ﬁrst (from facilities serving
the disease burden study) to produce estimates of the average
costs of the following: a day’s hospitalization, clinic visit, and
medicines and diagnostic tests. This information was combined
with data on payments to health facilities from the sample of
patients who were visited during the household surveys (for
medicines, tests, or other direct costs). The portion of the total
cost of treatment that was borne by the public sector was calcu-
lated as the provider cost of treatment minus any fees received
from patients for their treatment. Though public treatment cost
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Figure 1 Model of overall cholera vaccine effec-
tiveness as a function of vaccination coverage rate
in year 1 in herd protection scenario and compari-
son with results from epidemiological studies
[13,14].The results shown from Longini et al. [14]
assume vaccine effectiveness against susceptibility
is 60% and efﬁcacy against infectiousness is 50%.
Estimates for effectiveness in year 3 were adjusted
down by 17% to represent the vaccine’s waning
protection in time.
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studies in each country were not identical because of differences
in the health care systems, availability of data, and the design of
the DOMI projects in each country, similar components were
measured to maximize comparability of ﬁndings (Poulos C,
Riewpaiboon A, Stewart JF, et al., unpubl. data).
It should be noted that the public cost studies in Matlab,
Kolkata and Beira only collected complete data for hospitalized
patients, though hospitalization rates in Matlab and Beira were
nearly 100%. In Kolkata, where the hospitalization rate was
51%, public COI estimates may be overestimated.
Coverage. DOMI studies estimated private demand for cholera
vaccines; these were used to predict coverage levels for different
ages given the provision of a free vaccine [21–23]. Our estimates
of vaccine coverage were adjusted to account for the effect of
giving respondents time to think about their demand for vac-
cines. Several of these studies of private demand for cholera and
typhoid vaccines have found that respondents given the oppor-
tunity to consider a vaccine scenario overnight express more
certainty about their responses and lower willingness to pay.
Coverage rates predicted by these studies varied from 24%
among adults in North Jakarta to 74% among young children in
Kolkata, but were typically between 50% and 60% (Table 1).
For sensitivity analysis, we allowed these estimates to range from
a 25% decrease in coverage from these base coverage levels to the
unadjusted (“no time-to-think”) demand estimates (which were
10–30% higher depending on the site and age group). We also
assumed that 80% of people would be informed of the vaccina-
tion effort in each site (range 60–100%).
Cost of vaccination. The social cost of a cholera vaccination
program is composed of three main components: 1) the cost of
acquiring vaccines from the manufacturer; 2) the cost of delivering
and administering the vaccine to the target population; and 3) the
time and pecuniary costs incurred by household members to travel
to the vaccination outpost and to wait to receive the vaccine. None
of the three cost components is known with certainty. They
depend on a number of factors for which there is little information
in the published vaccine cost literature. For cost estimates in the
present analysis, we relied on a recent review and analysis of this
literature by D. Lauria and J. Stewart (unpubl. ms.) and on data
collected during other vaccine demonstration projects (for
typhoid) in several DOMI study sites, the cholera vaccine
demonstration project in Beira, Mozambique, and the Phase III
clinical trial of the WC vaccine in Kolkata.
We assumed a vaccine cost, including shipping and wastage,
of US$0.60 per dose in the base case, in all sites (range US$0.4–
0.8), derived from the estimated production costs of the Viet-
namese vaccine [24]. We use the same base case acquisition cost
for all sites, because the cost of customs, freight and insurance
are within the overall margin of error.
We followed a commonly used convention in the cost-
effectiveness literature (see Sinha et al. [25] for a recent example)
and assumed that delivery costs are captured in a constant mar-
ginal cost per vaccinated individual rather than including ﬁxed
(i.e., set up) costs. This implies constant returns to scale in
vaccination. We assumed that the marginal delivery cost per dose
is the same for a school-based program (Options 1 and 2) as for
a community-based vaccination program (Option 3). For the
sites in Bangladesh, India, and Mozambique, we used Lauria and
Stewart’s estimate of US$0.50 per dose for delivery costs in the
low-income countries. For Indonesia, we used Lauria and Stew-
art’s estimate of US$1.0 per dose for middle-income countries.
In the sensitivity analyses, we based the uncertainty ranges on
the 16 studies for low-income countries reviewed by Lauria and
Stewart. The 12.5% to 87.5% conﬁdence interval (obtained by
dropping the two highest and two lowest delivery cost estimates)
is US$0.3–US$2.5 per dose, which we use as the lower and upper
bounds in the sensitivity analysis. Because their study only
included 6 middle-income countries and because costs are
assumed to be twice as high in middle income countries, we
derived the uncertainty range for Indonesia by doubling the
range described above for low-income countries, or US$0.6–
US$5.0 per dose.
Results
Base-Case Analysis
Table 3 presents results for the three program options when herd
protection is ignored. Consistent with conventional wisdom, no
programs are very cost-effective using the commonly cited
threshold of per capita GDP. The ratios are best for programs
that reach the youngest children because the disease mostly
affects the young in these sites (see Table 1).
When vaccine herd protection is incorporated, this picture
changes (Table 4). Depending on the program, the predicted
Table 2 Components of ex post private and public costs of illness
Component Private costs Public costs
Direct Costs Treatment—including: Publicly borne costs of:
Diagnostic tests An outpatient visit in a public clinic
A day of hospitalization in a public hospital
The medicines received by the patient in the treatment of the disease
The diagnostic tests used for patients with the disease.
Medicine
Examination
Bed charges*
Transportation
Nonmedical items—including foods and beverages
used to aid treatment
Lodging and meals for other persons†
Other payments
Indirect Costs Patient’s lost income/production Not applicable
Substitute laborers’ net lost income/production‡
Caretakers’ lost income/production
Other persons’ lost income/production
*These were most often persons who accompanied the patient when they sought treatment.
†If there is an overnight stay.
‡This is “net” because substitute laborers result in a net increase or decrease in lost productivity. On the one hand, they can increase losses if they are not able to perform their own work.
On the other hand, they reduce losses when they replace patients’ lost labor.This item is equal to (substitute laborers’ own lost income/production) + (substitute laborers’ contributions to
income/production by doing patients’ work).
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number of cases avoided increases by a factor of 3 to 10 over the
estimates that ignore herd effects. The largest reduction in disease
burden is in Beira, with 2615, 3393, and 5692 cases of cholera
avoided for Options 1, 2, and 3, respectively, when accounting
for herd protection, in comparison with 322, 672, and 1772
cases without. In Kolkata, the cases avoided for Option 3
increase threefold, from 244 to 779. Though the GDP per capita
cutoffs are somewhat arbitrary, all three programs in Beira and
Kolkata are considered very cost-effective. In Matlab, Option 1 is
very cost-effective, and the other two options are cost-effective.
The ratios are higher in North Jakarta due to the higher assumed
cost of vaccination and lower cholera incidence, but higher per
capita GDP in Indonesia makes results for all three programs
cost-effective.
Uncertainty Analysis
Sensitivity analysis reveals that ﬁve model parameters have a
large inﬂuence on the ratios in these different sites: the cost of
vaccination, incidence, the CFR, the vaccine’s duration, and the
extent of herd protection (Table 5). Parameters such as the public
COI, DALY weight, duration of illness, and coverage rates are
relatively less important. The cost per fully vaccinated person
contributes the most to uncertainty in ratios in all sites, for all
program options. Figure 2 facilitates the comparison of sensitiv-
ity to cost across sites. It also shows the consequences of ignoring
vaccine herd protection: there is little chance that any program
would be considered very cost-effective even under the optimistic
assumptions about the cost per fully vaccinated person if herd
protection is ignored. In addition, ignoring herd protection
effects could lead to choosing less cost-effective programs. For
example, in Beira, one might mistakenly favor community-based
mass vaccination over vaccination of school children.
Discussion
Several observations emerge from this analysis. First, even vac-
cination programs that include only school children proved suf-
ﬁcient to provide substantial reductions in the overall burden of
cholera through herd protection. For example, in Beira, where a
program targeted at school children delivers about 66,000 vac-
cines for a population coverage rate of 12%, the overall protec-
tion rate was 38% (Fig. 1). As a result of indirect protection, it
has been found that the number of cases avoided is over eight
times than when herd protection is not included in the analysis.
Importantly, infants who are too young to be safely vaccinated
receive some protection [26]. These cost-effectiveness results
with herd protection are dependent on the coverage rate that is
assumed because vaccine efﬁcacy is a function of coverage rates.
Table 3 Key vaccination program outcomes without herd protection effects
Parameters
Matlab,
Bangladesh
Kolkata,
India
N. Jakarta,
Indonesia
Beira,
Mozambique
Option 1: School-based program targeting school children (5–14 years)
Number vaccinations 21,296 16,036 14,421 65,938
Cases avoided over 3 years 56 60 7 322
% Reduction in cases 5 6 3 5
Deaths avoided over 3 years 1 1 0 3
DALYs avoided over 3 years 15 16 2 78
Public COI avoided $1,083 $873 $181 $8,125
Total program costs $46,851 $35,279 $46,146 $145,064
Average cost per vaccinee $2.2 $2.2 $3.2 $2.2
Net public cost (Total program costs—Public COI avoided) $45,768 $34,405 $45,965 $136,939
Net public cost per case avoided $813 $578 $6,418 $426
Net public cost per death avoided $81,265 $57,768 $641,825 $42,555
Net public cost per DALY avoided $2,999 $2,125 $23,415 $1,748
Option 2: School-based program targeting all 1–14 year olds
Number vaccinations 34,475 23,702 19,712 89,282
Cases avoided over 3 years 141 151 21 672
% Reduction in cases 14 16 10 10
Deaths avoided over 3 years 1 2 0 7
DALYs avoided over 3 years 39 42 6 166
Public COI avoided $2,708 $2,212 $532 $16,956
Total program costs $75,845 $52,145 $63,077 $196,420
Average cost per vaccinee $2.2 $2.2 $3.2 $2.2
Net public cost $73,137 $49,932 $62,545 $179,464
Net public cost per case avoided $519 $331 $2,970 $267
Net public cost per death avoided $51,929 $33,097 $297,008 $26,725
Net public cost per DALY avoided $1,886 $1,199 $10,632 $1,081
Option 3: Community-based program (all persons 1 year and older)
Number vaccinations 72,653 82,796 38,473 257,595
Cases avoided over 3 years 207 244 30 1,772
% Reduction in cases 20 25 14 26
Deaths avoided over 3 years 2 2 0 18
DALYs avoided over 3 years 54 63 8 383
Public COI avoided $3,884 $4,017 $735 $48,907
Total program costs $159,836 $182,150 $123,112 $566,710
Average cost per vaccinee $2.2 $2.2 $3.2 $2.2
Net public cost $155,952 $178,133 $122,378 $517,802
Net public cost per case avoided $752 $731 $4,131 $292
Net public cost per death avoided $75,208 $73,071 $413,111 $29,223
Net public cost per DALY avoided $2,897 $2,836 $15,576 $1,353
GDP Thresholds (for reference)
Cost-effective (3 ¥ GDP/cap) $1,458 $2,613 $5,436 $1,146
Very cost-effective (GDP/cap) $486 $871 $1,812 $382
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Second, as shown in Figure 1, the rate of increase of overall
vaccine protection decreases as a function of coverage; i.e., the
marginal effect of increased herd protection decreases as cover-
age increases. As a result, effective targeting can keep program
costs low while still conferring signiﬁcant protection to the popu-
lation as a whole. When herd protection is ignored, programs
targeting the highest incidence age group (children aged 1–4) are
clearly the most cost-effective (Table 3). However, if herd protec-
tion is incorporated in the analysis, in all four sites, the cost-
effectiveness of programs targeting school children (ages 5–14) is
similar to that of programs targeting all eligible children (ages
1–14), despite the differences in incidence among age groups
Table 4 Key vaccination program outcomes with herd protection effects*
Parameters
Matlab,
Bangladesh
Kolkata,
India
N. Jakarta,
Indonesia
Beira,
Mozambique
Option 1: School-based program targeting school children (5–14 years)
Number vaccinations 21,296 16,036 14,421 65,938
Cases avoided over 3 years 341 301 65 2,615
% Reduction in cases 33 31 30 38
Deaths avoided over 3 years 3 3 1 26
DALYs avoided over 3 years 87 78 17 576
Public COI avoided $6,360 $4,875 $1,604 $71,254
Net public cost $40,491 $30,404 $44,542 $73,810
Net public cost per case avoided $119 $101 $687 $28
Net public cost per death avoided $11,877 $10,106 $68,703 $2,823
Net public cost per DALY avoided $463 $390 $2,616 $128
Option 2: School-based program targeting all 1–14 year olds
Number vaccinations 34,475 23,702 19,712 89,282
Cases avoided over 3 years 517 448 91 3,393
% Reduction in cases 50 47 42 49
Deaths avoided over 3 years 5 4 1 34
DALYs avoided over 3 years 133 117 24 751
Public COI avoided $9,651 $7,201 $2,243 $92,244
Net public cost $66,194 $44,944 $60,835 $104,176
Net public cost per case avoided $128 $100 $672 $31
Net public cost per death avoided $12,810 $10,041 $67,202 $3,071
Net public cost per DALY avoided $497 $384 $2,542 $139
Option 3: Community-based program (all persons 1 year and older)
Number vaccinations 72,653 82,796 38,473 257,595
Cases avoided over 3 years 749 779 135 5,692
% Reduction in cases 73 81 62 82
Deaths avoided over 3 years 7 8 1 57
DALYs avoided over 3 years 191 200 35 1241
Public COI avoided $13,927 $12,836 $3,322 $156,188
Net public cost $145,909 $169,314 $119,790 $410,522
Net public cost per case avoided $195 $217 $891 $72
Net public cost per death avoided $19,471 $21,744 $89,052 $7,212
Net public cost per DALY avoided $764 $845 $3,400 $331
GDP Thresholds (for reference)
Cost-effective (3 ¥ GDP/cap) $1,458 $2,613 $5,436 $1,146
Very cost-effective (GDP/cap) $486 $871 $1,812 $382
*Note that the total program costs, and average cost per immunized person are the same as those reported in Table 2.
Table 5 Effect of individual parameters on cost-effectiveness ratios (2007US$ per DALY avoided), ranked in order of signiﬁcance to variation in results*
Most important Second Third Fourth Fifth
Parameter Low–High Parameter Low–High Parameter Low–High Parameter Low–High Parameter Low–High
Matlab, Bangladesh
Program Option 1 Cost 259–1,525 Incidence 186–989 CFR 151–905 Duration 338–666 Herd extent 424–673
Program Option 2 Cost 281–1,627 Incidence 203–1,057 CFR 163–973 Duration 365–713 Herd extent 456–721
Program Option 3 Cost 450–2,429 Incidence 336–1,592 CFR 252–1,506 Duration 574–1,086 Herd extent 708–1,097
Kolkata, India
Program Option 1 Cost 211–1,280 Incidence 150–828 CFR 125–750 Duration 278–555 Herd extent 350–561
Program Option 2 Cost 209–1,263 Incidence 148–817 CFR 124–740 Duration 275–548 Herd extent 346–554
Program Option 3 Cost 499–2,649 CFR 277–1,657 Incidence 375–1,740 Duration 634–1,190 Herd extent 780–1,203
N. Jakarta, Indonesia
Program Option 1 Cost 1,587–9,717 CFR 869–5,195 Incidence 1,248–5,313 Duration 2,018–3,676 Herd extent 2,452–3,713
Program Option 2 Cost 1,541–9,449 CFR 844–5,048 Incidence 1,211–5,165 Duration 1,960–3,573 Herd extent 2,383–3,609
Program Option 3 Cost 2,078–12,560 CFR 1,131–6,761 Incidence 1,641–6,882 Duration 2,633–4,772 Herd extent 3,193–4,819
Beira, Mozambique
Program Option 1 Cost 12–607 Incidence (-22)–356 CFR 35–207 Duration 49–203 Herd extent 90–207
Program Option 2 Cost 19–637 Incidence (-16)–376 CFR 38–228 Duration 58–218 Herd extent 100–221
Program Option 3 Cost 140–1,219 Incidence 77–762 CFR 102–610 Duration 207–487 Herd extent 280–493
*Assumes herd protection; Program Option 1 targets only school-aged children (5–14.9); Option 2 also includes young children (1–4.9); Option 3 is a mass program targeting all ages; reported
uncertainty ranges correspond to parameter ranges speciﬁed in Table 1.
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(Table 4). This is because a proportionally larger share of herd
protection beneﬁts is captured by the smaller program that only
includes school children. For example, in Kolkata, expanding the
program to include 1 to 4 year olds as well as 5 to 14 year olds
leads to a 16% increase in reduction of the disease burden, but
the ratio hardly changes. In general, the most cost-effective
options would be programs designed to target eligible young
children (1–4 years old) and other vulnerable populations while
still achieving sufﬁcient overall coverage to capture herd protec-
tion beneﬁts.
Third, community-based vaccination programs that include
adults are shown to be generally less cost-effective than interven-
tions targeted at all eligible children. The reasons for the lower
cost-effectiveness of adult interventions differ depending on
whether the herd protection effect is incorporated into the analy-
sis. If herd protection is ignored, the lower incidence among
adults would suggest better prospects from designing programs
aimed at children. If herd protection is taken into account, going
from small programs targeting only school children to somewhat
larger programs for all eligible children provides direct and herd
protection beneﬁts that are comparable to added vaccination
costs. However, moving from child-only programs to vaccinating
both children and adults requires expenses that rise faster than
do the additional protective beneﬁts of vaccination. The dimin-
ishing health returns from vaccinating additional people are a
direct consequence of the diminishing marginal effect of herd
protection, shown in Figure 1.
Fourth, the cost-effectiveness and disease burden reduction of
cholera vaccination vary substantially across the sites studied.
The ratios for Beira are on par with some of the more cost-
effective health interventions considered in the Disease Control
Priorities Project ($100 or less). Next in line, Kolkata and Matlab
have similar ratios ($350–$500), but the relative value of these
programs depends on somewhat arbitrary thresholds for cost-
effectiveness (higher in Kolkata owing to higher per capita GDP).
North Jakarta has relatively low cholera incidence, and ratios
there are much higher. This variation emphasizes the importance
of using detailed site-speciﬁc data for disease incidence, mortality
rates and other population-speciﬁc parameters in the cost-
effectiveness analysis, and suggests that caution should be used in
extrapolating the cost-effectiveness ratios from these speciﬁc sites
to locations in other parts of the world. An additional difﬁculty
with generalizing the results from these sites is the substantial
uncertainty associated with the effect of herd protection in dif-
ferent locations. The only existing empirical study of this effect
comes from Matlab, Bangladesh.
Two particular limitations of our use of this herd protection
data from Bangladesh should be noted. First, herd protection
depends on location-speciﬁc conditions, such as the local disease
epidemiology and transmission. Because we did not have detailed
information about how such factors might inﬂuence herd pro-
tection against cholera, we applied the herd effects observed in
Bangladesh to our analyses of all study sites. Second, published
data and models of the herd protection only correspond to the
ﬁrst year following vaccination, whereas cholera immunizations
are generally thought to offer three-year protection, during which
time the direct effectiveness of the vaccine wanes. Data from the
Bangladesh trial do reveal that vaccine herd protective effects
were undiminished through two years of follow-up [M. Ali,
personal communication]. For year 3, we diminished the vaccine
herd protective effects by 17% to correspond with observed
decreases in direct effectiveness.
Cost-effectiveness ratios can provide a useful starting point
for comparing the relative value of using public monies for
cholera vaccination rather than other health interventions. The
ﬁnancial realities facing resource-deprived health systems in
developing countries make it impossible to carry out all poten-
tially “very cost-effective” interventions. The DCP Project
reports ratios of $7 and $68 per DALY avoided for scaled-up
Expanded Program on Immunization (EPI) programs and BCG
vaccine against tuberculosis, respectively; these interventions
thus appear more attractive than cholera vaccination [11].
However, the DCP’s ratio of $296 for concurrent Hib and Hepa-
titis B vaccination is higher than our ratio for cholera vaccine
programs for children in Beira. A number of other vaccines
included in the DCP’s report (e.g., Hib alone, hepatitis alone)
also have less attractive ratios than many of the cholera programs
analyzed in this article, although these vaccines may also show
herd protection effects. Incorporating these effects could improve
the cost-effectiveness of these vaccines as well.
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Figure 2 The inﬂuence of the cost of vaccination
on cost-effectiveness ratios (log scale).Thick gray
lines indicate the “very cost-effective” threshold;
dotted black lines the “cost-effective” threshold.
Program options (1, 2, and 3) are labeled above the
ranges. Ranges ignoring herd protection are dis-
played to the left; those incorporating these effects
are to the right.The lower bound of the range is
associated with the low cost shown in Table 1; the
upper bound is the high cost.
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Policymakers are especially interested in comparing the cost-
effectiveness of cholera vaccination programs with water and
sanitation interventions [11,15]. When herd protection is incor-
porated into the cost-effectiveness calculations, the results pre-
sented in this article suggest that in several locations (e.g., Beira,
Kolkata, and Matlab) cholera vaccination of children is likely to
compare favorably with the cost-effectiveness of water and sani-
tation interventions. However, cost-effectiveness ratios using
health outcomes are not the only basis for choosing between
cholera vaccination and water and sanitation interventions.
Other factors in the decision include the nonhealth beneﬁts
obtained from water and sanitation interventions, feasibility of
implementation, longevity of the interventions, and ﬁnancing
constraints [27,28]. Many water and sanitation interventions
provide protection against a range of diseases, and offer substan-
tial time savings and aesthetic lifestyle beneﬁts to households.
Cholera vaccination, however, only provides beneﬁts in the form
of reduced cost of illness and reduced mortality risk from a single
disease [28]. The beneﬁts from water and sanitation interven-
tions also last longer than the 3 years of protection offered by
cholera vaccines. On the other hand, water and sanitation inter-
ventions are much more capital intensive than cholera vaccina-
tion programs, and are therefore more difﬁcult to ﬁnance [28].
Finally, it may be difﬁcult in crowded urban areas to ﬁnd effective
low-cost water and sanitation interventions that deliver health
and time savings beneﬁts [27]. In such cases, cholera vaccination
may provide health improvements until the construction of new
housing and until associated water and sanitation infrastructure
is ﬁnancially feasible.
In addition to cost-effectiveness analysis, decision makers
should at least undertake a full economic cost-beneﬁt analysis
(CBA) before making decisions concerning cholera vaccination.
CBA would give a more complete picture of whether programs
should be implemented from a social perspective. The best pro-
grams might pass a CBA test and appear very cost-effective, but
some programs may be very cost-effective and fail a CBA test, or
vice versa. CEA makes an implicit assumption that every DALY
should be treated equally, which fails to account for heterogeneity
in risk preferences, vulnerability to disease, and demand for
improved health. Besides including public COI savings, economic
CBA would incorporate private costs of vaccination and beneﬁts
such as private COI savings, increased productivity and wages
from not missing work and private willingness to pay (WTP) for
avoided risks of death from disease and pain and suffering [29,30].
Where WTP for cholera protection among some members of the
population is high, the importance of vaccine herd protection
effects would argue for at least making vaccines available at cost in
pharmacies or health clinics, since the population as a whole
would beneﬁt from increased indirect protection.
In summary, our cost-effectiveness calculations that incorpo-
rate herd protection show that oral cholera vaccination of chil-
dren is more cost-effective than previously thought. Unlike the
results for cholera vaccines summarized in the DCP [11], we
show that cholera vaccination may in fact be cost-effective once
vaccine herd protection effects are taken into account, and given
the use of a cheaper alternative to the Dukoral™ vaccine.
Though the relationships between coverage, targeting, and pro-
tection in different types of settings call for further study, the
results presented here show that vaccinating children against
cholera should be strongly considered as a public health inter-
vention in Beira, Matlab, and Kolkata.
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